A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation.

TitleA non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation.
Publication TypeJournal Article
Year of Publication2018
AuthorsMichel BC, D'Avino AR, Cassel SH, Mashtalir N, McKenzie ZM, McBride MJ, Valencia AM, Zhou Q, Bocker M, Soares LMM, Pan J, Remillard DI, Lareau CA, Zullow HJ, Fortoul N, Gray NS, Bradner JE, Chan HMan, Kadoch C
JournalNat Cell Biol
Volume20
Issue12
Pagination1410-1420
Date Published2018 12
ISSN1476-4679
KeywordsCell Line, Tumor, Cell Proliferation, Chromatin, Chromatin Assembly and Disassembly, Chromosomal Proteins, Non-Histone, HEK293 Cells, Humans, Mutation, Nuclear Proteins, Promoter Regions, Genetic, Rhabdoid Tumor, RNA Interference, Sarcoma, Synovial, Transcription Factors
Abstract

Mammalian SWI/SNF chromatin remodelling complexes exist in three distinct, final-form assemblies: canonical BAF (cBAF), PBAF and a newly characterized non-canonical complex (ncBAF). However, their complex-specific targeting on chromatin, functions and roles in disease remain largely undefined. Here, we comprehensively mapped complex assemblies on chromatin and found that ncBAF complexes uniquely localize to CTCF sites and promoters. We identified ncBAF subunits as synthetic lethal targets specific to synovial sarcoma and malignant rhabdoid tumours, which both exhibit cBAF complex (SMARCB1 subunit) perturbation. Chemical and biological depletion of the ncBAF subunit, BRD9, rapidly attenuates synovial sarcoma and malignant rhabdoid tumour cell proliferation. Importantly, in cBAF-perturbed cancers, ncBAF complexes maintain gene expression at retained CTCF-promoter sites and function in a manner distinct from fusion oncoprotein-bound complexes. Together, these findings unmask the unique targeting and functional roles of ncBAF complexes and present new cancer-specific therapeutic targets.

DOI10.1038/s41556-018-0221-1
Alternate JournalNat. Cell Biol.
PubMed ID30397315
PubMed Central IDPMC6698386
Grant ListDP2 CA195762 / CA / NCI NIH HHS / United States
R01 CA237241 / CA / NCI NIH HHS / United States
T32 GM095450 / GM / NIGMS NIH HHS / United States